111 Speen Street, Suite 306
At Alzheon, we apply a precision medicine approach utilizing our scientific knowledge and clinical expertise to make advances in the challenging field of therapeutics for Alzheimer’s and other neurological disorders. Our efforts have resulted in ALZ-801, a novel, investigational medicine with an ideal profile for Alzheimer’s patients: an oral pill with favorable safety and the ability to interfere with the amyloid pathology that leads to Alzheimer’s disease.
77 articles with Alzheon
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ‑801 in Patients with Early Alzheimer’s Disease
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced the dosing of the first patient in its APOLLOE4 Phase 3 study evaluating the efficacy and safety of ALZ-801 in Early AD patients carrying two copies of the ε4 allele of the apolipoprotein E gene.
Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced that it has entered into a collaboration and license agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to develop the first clinical assay to measure neurotoxic beta amyloid oligomers in human cerebrospinal fluid.
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program.
A drug to halt the progression of Alzheimer’s disease will likely be approved within the next three years, and Alzheon’s ALZ-801 might be the leading candidate.
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit
Dr. Martin Tolar to Provide an Update on Alzheon’s ALZ-801 Phase 3 Program and Join Panel Discussion on Current Research in Alzheimer’s Disease
Biopharma companies may receive NIH funding, but generally, not to the extent that academia does. However, the Genetown Hotbed has several biopharma companies that received significant funds from the NIH in 2020. Here’s a look at the top 10.
Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease
Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
Alzheon, Inc. announced the initiation of a Phase 2 study evaluating biomarker effects of ALZ-801, an oral treatment blocking formation of neurotoxic soluble amyloid oligomers, in Early AD patients carrying one or two copies of the ε4 allele of the apolipoprotein E gene.
8/24/2020It was a relatively quiet week for clinical trial news. Here’s a look.
Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease
Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer’s Disease in Patients with APOE4/4 Genetic Profile
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker Results
Martin Tolar, chief executive officer of Alzheon, told BioSpace that his company’s drug was designed to inhibit the formation of toxic soluble amyloid oligomers.
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
Alzheon, Inc. announced that Christopher Noel Dunn, Jordan Heller, and Diane K. Jorkasky, MD, FACP, have been appointed to the company’s board of directors.
Industry veteran brings broad commercial expertise in neuroscience drug development and commercialization as Alzheon advances ALZ-801 into Phase 3 as potentially the first oral disease-modifying treatment for Alzheimer’s disease
Alzheon Announces Scientific Presentation at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Taking Place on December 4-7 in San Diego, USA
Cortical Thickness May Be a Useful Biomarker in Future Disease Modification Trials with High-Risk APOE4/4 Alzheimer’s Patients
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course
A 2013 study that analyzes IPO withdrawals between 1999 and 2004 found that about 13 percent returned later for a successful IPO, 36 percent turned again to raising capital privately, and 42 percent either merged or were acquired by other companies—another common strategy for biotechs. And about ...
Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.
The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange.